Suzanne Fussell, MD
Family Medicine · Oxnard, CANPI 1942394457
Payments from drug & device makers
Across 578 payments — averaging $15,331 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.6M
- Modernatx, Inc.$1.6M
- Amgen$1.3M
- Eisai Inc.$939K
- Novartis$626K
- Vertex$546K
- plus $1.4M from 31 others
Across 4 payments — averaging $1032.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$2K
- Lexicon Pharmaceuticals, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 179 | $2,551,632 |
| Modernatx, Inc. | 56 | $1,582,323 |
| Amgen | 3 | $1,258,267 |
| Eisai Inc. | 40 | $938,986 |
| Novartis | 42 | $625,675 |
| Vertex | 2 | $546,018 |
| Sumitomo Pharma America, Inc. | 50 | $361,767 |
| Sanofi US Services Inc. | 15 | $250,538 |
| AbbVie(2 entities) | 44 | $224,686 |
| GSK | 32 | $130,706 |
| Lexicon Pharmaceuticals, Inc. | 11 | $106,340 |
| AstraZeneca | 5 | $93,308 |
| E.r. Squibb & Sons, L.L.C. | 10 | $92,949 |
| Boehringer Ingelheim | 3 | $28,123 |
| Boehringer Ingelheim Canada Ltd.ltee | 33 | $21,427 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11,800 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $10,900 |
| Vanda Pharmaceuticals Inc. | 3 | $10,000 |
| Myovant Sciences Inc. | 2 | $5,895 |
| Sanofi Pasteur Inc. | 5 | $5,143 |
| Lupin Inc. | 1 | $3,283 |
| Exact Sciences | 6 | $330 |
| Cipher Pharmaceuticals US LLC | 1 | $285 |
| Lilly USA, LLC | 7 | $158 |
| Novo Nordisk | 5 | $150 |
| Hologic Sales And Service, LLC | 5 | $125 |
| Abbott | 2 | $49 |
| Exeltis, USA Inc. | 2 | $47 |
| Genentech USA, Inc. | 3 | $44 |
| Boston Scientific | 1 | $43 |
| Gilead | 2 | $36 |
| Seqirus USA Inc | 1 | $25 |
| Nevro Corp. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Vertiflex, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
How this compares
$8,861,153 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Oxnard
- Augusto FocilOxnard$12.6M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Jack VuLong Beach$10.1M
- Joanna vanColton$8.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.